Tinzaparin

Generic Name: Tinzaparin

Brand Names: Innohep

Drug Type: Small Molecule

CAS Number: 9041-08-1

Unique Ingredient Identifier: 7UQ7X4Y489

Background: Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for high affinity binding to antithrombin III (ATIII). This complex greatly accelerates the inhibition of factor Xa. It is an anticoagulant and considered an antithrombotic. Tinzaparin must be given either subcutaneously or parenterally. LMWHs are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.

Indication: Tinzaparin is used for the prevention of postoperative venous thromboembolism in patients undergoing orthopedic surgery and in patients undergoing general surgery who are at high risk of developing postoperative venous thromboembolism. It is also used for the treatment of deep vein thrombosis and/or pulmonary embolism. It is indicated for use in preventing clot formation in indwelling intravenous lines for hemodialysis.

Associated Conditions: Clotting, Deep Vein Thrombosis, Pulmonary embolism, Deep vein thrombosis, Venous Thromboembolism

Clinical Trials

Evaluation of Long-Term Sequelae After Thrombophlebitis, i.e. Deep Venous Thrombosis of the Lower Extremities

Phase 3

Completed

Conditions: Deep Venous Thrombosis

Interventions: Drug: unfractionated heparin
Drug: Tinzaparin (Leo)

First Posted Date: 2008-03-05

Last Posted Date: 2008-03-05

Lead Sponsor: Aalborg University Hospital

Target Recruit Count: 99

Registration Number: NCT00628576

Locations: 🇩🇰
Dept. of Haematology; Aalborg Hospital, Aalborg, Region Nordjylland, Denmark

Effect of Low Molecular Weight Heparin: Tinzaparin in Lung Tumours (TILT)

Phase 3

Completed

Conditions: Non Small Cell Lung Cancer
Lung Cancer

Interventions: Drug: Tinzaparin sodium 100 UI/Kg/OD for 12 weeks

First Posted Date: 2007-05-17

Last Posted Date: 2016-09-02

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 553

Registration Number: NCT00475098

Locations: 🇫🇷
Hopital Européen Georges Pompidou, Paris, France

Effects of Tinzaparin on Cardio-vascular Outcomes and on Blood Lipids in Diabetic Patients on Chronic Hemodialysis

Phase 4

Withdrawn

Conditions: Diabetes Mellitus
Hemodialysis

Interventions: Drug: Tinzaparin administration
Drug: Heparin administration

First Posted Date: 2006-12-05

Last Posted Date: 2017-12-22

Lead Sponsor: Anemia Working Group Romania

Registration Number: NCT00407641

Locations: 🇷🇴
Bihor County Hospital, Oradea, Romania
🇷🇴
Timisoara County Hospital, Timisoara, Romania
🇷🇴
Cluj University Hospital, Cluj, Romania

and more 10 locations

Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery

Phase 1

Conditions: Kidney Cancer

First Posted Date: 2006-02-17

Last Posted Date: 2013-11-06

Lead Sponsor: University of Vermont

Target Recruit Count: 35

Registration Number: NCT00293501

Locations: 🇺🇸
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Vermont Cancer Center at University of Vermont, Burlington, Vermont, United States

Innohep® in Elderly Patients With Impaired Renal Function Treated for Acute Deep Vein Thrombosis

Phase 4

Completed

Conditions: Deep Vein Thrombosis

Interventions: Drug: innohep®
Drug: Heparin

First Posted Date: 2006-01-16

Last Posted Date: 2025-03-06

Lead Sponsor: LEO Pharma

Target Recruit Count: 541

Registration Number: NCT00277394

Locations: 🇫🇷
Hôpital de la Cavale Blanche, Brest, France
🇧🇬
Bulgaria - managed by CRO, Sofia, Bulgaria
🇨🇿
Czech Republic - managed by CRO, Praha, Czechia

and more 6 locations